Discover
PLRX
Pliant Therapeutics, Inc.
1.11
2 x 0.83
2 x 1.45
bid
ask
-
0.03
2.63%
2 @ 04:00 PM
1.11 +0.00 (0.00%)
| Ytd | -9.02% | |
| 1y | -5.13% |
1.11
day range
1.16
1.09
52 week range
1.95
| Open | 1.12 | Prev Close | 1.14 | Low | 1.11 | High | 1.16 | Mkt Cap | 68.73M |
| Vol | 308.37K | Avg Vol | 465.24K | EPS | -1.83 | P/E | N/A | Forward P/E | -3.32 |
| Beta | 1.09 | Short Ratio | 15.30 | Inst. Own | 111.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.19 | 200-d Avg | 1.34 | 1yr Est | 40.18 |
| Income Statement | |||
| Operating Expenses | 21.77M | ||
| Research and Development Expense | 13.58M | ||
| Selling, General and Administrative Expense | 8.19M | ||
| Operating Income | -21.77M | ||
| Net Income | -20.04M | ||
| Net Income Common Stock | -20.04M | ||
| Net Income Common Stock (USD) | -20.04M | ||
| Consolidated Income | -20.04M | ||
| Earnings per Basic Share | -0.32 | ||
| Earnings per Basic Share (USD) | -0.32 | ||
| Earnings per Diluted Share | -0.32 | ||
| Earning Before Interest & Taxes (EBIT) | -20.04M | ||
| Earning Before Interest & Taxes (USD) | -20.04M | ||
| Weighted Average Shares | 61.80M | ||
| Weighted Average Shares Diluted | 61.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 23.67M | ||
| Cash and Equivalents (USD) | 23.67M | ||
| Investments | 148.70M | ||
| Investments Current | 148.70M | ||
| Current Assets | 174.93M | ||
| Property, Plant & Equipment Net | 26.70M | ||
| Total Assets | 202.60M | ||
| Debt Current | 1.71M | ||
| Total Debt | 28.78M | ||
| Current Liabilities | 10.36M | ||
| Debt Non-Current | 27.07M | ||
| Total Liabilities | 37.43M | ||
| Accumulated Retained Earnings (Deficit) | -879.44M | ||
| Accumulated Other Comprehensive Income | -341.00K | ||
| Shareholders Equity | 165.17M | ||
| Shareholders Equity (USD) | 165.17M | ||
| Assets Non-Current | 27.67M | ||
| Total Debt (USD) | 28.78M | ||
| Liabilities Non-Current | 27.07M | ||
| Trade and Non-Trade Payables | 362.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.10M | ||
| Net Cash Flow from Financing | 74.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -23.25M | ||
| Capital Expenditure | 102.00K | ||
| Issuance (Purchase) of Equity Shares | 74.00K | ||
| Net Cash Flow from Investing | -4.10M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -4.20M | ||
| Net Cash Flow from Operations | -19.23M | ||
| Share Based Compensation | 4.25M | ||